Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

10.85CNY
2:59am EDT
Change (% chg)

¥-0.18 (-1.63%)
Prev Close
¥11.03
Open
¥11.03
Day's High
¥11.07
Day's Low
¥10.79
Volume
6,153,972
Avg. Vol
6,324,162
52-wk High
¥15.08
52-wk Low
¥10.64

Latest Key Developments (Source: Significant Developments)

Zhejiang Hisun Pharmaceutical receives administrative order
Tuesday, 25 Apr 2017 05:10am EDT 

April 25(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report .  Full Article

Zhejiang Hisun Pharmaceutical amends FY 2016 net profit outlook
Wednesday, 29 Mar 2017 06:00am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says net loss for FY 2016 is 94 million yuan . Says in the previous outlook, the company expected the net profit for FY 2016 to increase by 260 percent to 300 percent . Says the net profit of FY 2015 was 13.6 million yuan .Comments that increased advance receipts instead of revenue is the main reason for the forecast.  Full Article

Zhejiang Hisun Pharmaceutical gets approval for three drugs to enter clinical trials
Thursday, 16 Mar 2017 06:03am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says it got approval from China Food and Drug Administration to do clinical trials for three kinds of crud drugs .The three drugs are used for pulmonary tuberculosis, mammary cancer and hematological malignancies treatment respectively.  Full Article

Zhejiang Hisun Pharmaceutical receives GMP certificate
Wednesday, 15 Mar 2017 03:36am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says it received goods manufacture practice(GMP) certificate from Zhejiang Food and Drug Administration .Says the certificate issued to lyophilized powder for injection manufactured by the co and the valid period is until March 5, 2022.  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 09:00am EDT 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Zhejiang Hisun Pharmaceutical unit gets GMP certificate
Sunday, 24 Jul 2016 10:53pm EDT 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives goods manufacture practice (GMP) certificate .Says certificate issued to the unit's imported drug packing production line and the valid period is until July 3, 2021.  Full Article

Zhejiang Hisun Pharmaceutical signs $3 mln technology transfer agreement with Nascent
Monday, 18 Jul 2016 10:52pm EDT 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>:Says it signs $3 million technology transfer agreement with Nascent Biotech, Inc, to get exclusive right for Pritumumab, a targeted therapy for epithelioma.  Full Article

Zhejiang Hisun Pharmaceutical unit passes FDA approval
Monday, 27 Jun 2016 01:15am EDT 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives ANDA approval for its irbesartan tablets from U.S Food and Drug Administration .Says company's unit will be able to sell its irbesartan tablets in the United States after receiving the FDA approval.  Full Article

Japan's Fujifilm says signed patent licensing agreement with China's Zhejiang Hisun Pharmaceutical involving drug Avigan- Nikkei
Wednesday, 22 Jun 2016 11:24am EDT 

Nikkei: Japan's Fujifilm has signed patent licensing agreement with china's Zhejiang Hisun Pharmaceutical involving drug Avigan,used to treat ebola - Nikkei .Fujifilm Holdings unit said Chinese drugmaker may use patents on effective ingredient of Avigan to develop and market flu treatment in China - Nikkei.  Full Article

Zhejiang Hisun Pharmaceutical unit gets GMP certificate
Thursday, 26 May 2016 02:10am EDT 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS> : Says its unit receives goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration .Says certificate issued to sirolimus and tacrolimus manufactured by the unit.  Full Article

More From Around the Web

BRIEF-Zhejiang Hisun Pharmaceutical receives administrative order

* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report